Cargando…
Hypoxia-specific targets in cancer therapy: role of splice variants
Tumour hypoxia is a well known adverse prognostic factor in the treatment of solid tumours. Hypoxia-inducible factor 1α (HIF-1α), a transcription factor subunit regulating a large number of hypoxia-responsive genes, is considered an attractive target for novel treatment approaches, due to a frequent...
Autor principal: | Vordermark, Dirk |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909930/ https://www.ncbi.nlm.nih.gov/pubmed/20624302 http://dx.doi.org/10.1186/1741-7015-8-45 |
Ejemplares similares
-
Ten years of progress in radiation oncology
por: Vordermark, Dirk
Publicado: (2011) -
Targeting the hypoxia pathway to treat pancreatic cancer
por: Erickson, Lori A, et al.
Publicado: (2015) -
Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019) -
Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy
por: Riddell, Stanley R.
Publicado: (2004) -
Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients
por: Hahnel, Antje, et al.
Publicado: (2012)